Shares of New Zealand medicinal cannabis company Rua Bioscience (RUA.NZ) slid 7.1% to NZ$0.03 after the company disclosed its rights offer raised just NZ$1.0 million — barely a third of the NZ$2.8 million it sought — leaving critical working-capital needs unfunded and raising pointed questions about whether the company can continue operating without further emergency fundraising. Rua Bioscience Raises Just a Third of What It Needed — How Long Can a Three-Cent Stock Keep the Lights On?
Shares of NZ-listed medicinal cannabis firm Rua Bioscience dropped 7.1% to NZ$0.03 after the company revealed its rights offer pulled in barely a third of its fundraising target, leaving a gaping hole in its working-capital budget and raising urgent questions about how the company finances its next chapter.
Most Shareholders Stayed on the Sidelines
Rua's 1-for-3 renounceable rights offer, priced at $0.025 per new share, closed on October 15 and raised approximately NZ$1.0 million.
Eligible shareholders subscribed for just 39.6 million new shares — roughly 12% of existing shares — against the approximately 113 million shares the company had planned to issue. That means roughly two-thirds of shareholders declined to put up fresh cash, even at a 32% discount to the recent trading price. When insiders and loyalists can't fill a $2.8 million ask, the market is effectively saying the equity is too risky at any price.
The Funding Gap Threatens a Pivotal Export Deal
The capital was earmarked primarily to fund inventory and working capital to meet growing customer demand, particularly under Rua's largest export agreement to date in the United Kingdom — a deal expected to generate NZ$10 million in revenue over its initial two-year term. Chair Anna Stove acknowledged the shortfall bluntly: "The approximately $1.0 million raised… is below the $2.8 million sought and does not fully meet the company's working capital requirements." Without cash to build inventory, Rua risks failing to deliver on the contract that underpins its entire growth narrative.
Losses Keep Burning While Revenue Remains Tiny
FY26 revenue from customers grew 71% to $2.6 million, yet the company still posted a $3.36 million pre-tax loss.
Cash on hand stood at just NZ$534,000 as of the last annual report, while operating cash outflow widened to $3.0 million. Simple arithmetic: at that burn rate, the $1 million in fresh proceeds buys roughly four months of runway.
The Board Says It Can Find More Money — But the Track Record Is Wobbly
Rua says it will seek to place remaining shortfall shares and continue discussions with existing investors to secure additional funding. But this is the company's second disappointing rights offer in two years — a late-2024 raise also fell short, bringing in only $1.2 million.
Listed at 70 cents in 2020, the stock now trades at three cents — a 96% decline that makes each successive capital raise more dilutive and harder to fill.